GlassScriptPhysician profile
Emmanuel Edoka
NPI 1598857682
$2,080.57
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $663 · 2021: $377 · 2023: $138 · 2024: $44.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $182.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $384.08 | 2019-2021 | |
| Amgen INC. | $365.33 | 2019-2023 | Otezla |
| Lilly USA, LLC | $326.99 | 2019-2021 | |
| Astellas Pharma US INC | $223.53 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.20 | 2019-2021 | |
| Novo Nordisk INC | $205.31 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $90.61 | 2019 | |
| Allergan, INC. | $58.28 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $46.29 | 2019-2021 | |
| Abbott Laboratories | $37.15 | 2023-2024 | Proclaim |
| Takeda Pharmaceuticals U.S.A., INC. | $32.64 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.93 | 2020-2021 | |
| Dexcom, INC. | $24.60 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $21.63 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $16.96 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Edoka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.